Loss of PKR activity in chronic lymphocytic leukemia

International Journal of Cancer

Volumn 109, Issue 3, 2004, Pages 329-335

  Hii, Su Ing ^a   Hardy, Lani ^a   Crough, Tania ^a   Payne, Elizabeth J ^a   Grimmett, Karen ^c   Gill, Devinder ^a,b   McMillan, Nigel A J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c Queeensland Hlth Pathology Services   (Australia)

Author keywords

B CLL; DsRNA; Interferon; P58IPK; PACT; PKR

Indexed keywords

CD38 ANTIGEN; CHLOROFORM; DOUBLE STRANDED RNA; PHENOL; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE R; PROTEIN P53; PROTEIN P58; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER CELL CULTURE; CANCER STAGING; CELL LYSATE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; ENZYME SUBSTRATE; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; MALE; PARAMETER; PRIORITY JOURNAL; PROTEIN RNA BINDING; ULTRAFILTRATION;

ADP-RIBOSYL CYCLASE; AGED; ANTIGENS, CD; ANTIGENS, CD38; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 13; DOWN-REGULATION; EIF-2 KINASE; ENZYME ACTIVATION; FEMALE; GENE DELETION; HSP40 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; PHOSPHORYLATION; POLY I-C; REPRESSOR PROTEINS; RNA, DOUBLE-STRANDED; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1342288453     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11714     Document Type: Article

References (49)

1. Cordone I, Matutes E, Catovsky D. Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity. Leukemia 1992;6:902-6.
2. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. B-cell chronic lymphocytic leukemia: present status and future directions - French Cooperative Group on CLL. Blood 1991;78:1901-14.
3. Hamblin TJ, Oscier DG. Chronic lymphocytic leukaemia: the nature of the leukaemic cell. Blood Rev 1997;11:119-28.
4. MacLennan IC, Gray D. Antigen-driven selection of virgin and memory B cells. Immunol Rev 1986;91:61-85.
5. Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980;55:282-93.
6. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176:1319-26.
7. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
8. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989;71:343-50.
9. Orsini E, Guarini A, Foa R. Accessory cells, cytokine loops and cell-to-cell interactions in chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:73-98.
10. Gongora R, Stephan RP, Zhang Z, Cooper MD. An essential role for Daxx in the inhibition of B lymphopoiesis by type I interferons. Immunity 2001;14:727-37.
11. Mainou-Fowler T, Prentice AG. Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 1996;21:369-77.
12. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene 1999;18:6112-20.
13. Chong KL, Feng L, Schappert K, Meurs E, Donahue TF, Friesen JD, Hovanessian AG, Williams BR. Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. Embo J 1992;11:1553-62.
14. Thomis DC, Samuel CE. Mechanism of interferon action: autoregulation of RNA-dependent P1/eIF-2 alpha protein kinase (PKR) expression in transfected mammalian cells. Proc Natl Acad Sci USA 1992;89:10837-41.
15. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. Embo J 1998;17:6888-902.
16. Saelens X, Kalai M, Vandenabeele P. Translation inhibition in apoptosis: caspase-dependent PKR activation and eIF2-alpha phosphorylation. J Biol Chem 2001;276:41620-8.
17. Barber GN, Wambach M, Thompson S, Jagus R, Katze MG. Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. Mol Cell Biol 1995;15:3138-46.
18. Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 1992;257:1685-9.
19. Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 1993;90:232-6.
20. Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, Kumar A, Williams BR, Aguet M, Weissmann C. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. Embo J 1995;14:6095-106.
21. Abraham N, Stojdl DF, Duncan PI, Methot N, Ishii T, Dube M, Vanderhyden BC, Atkins HL, Gray DA, McBurney MW, Koromilas AE, Brown EG, Sonenberg N, Bell JC. Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. J Biol Chem 1999;274:5953-62.
22. Berger R, Flandrin G, Bernheim A, Le CM, Vecchione D, Pacot A, et al. Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias. Cancer Genet Cytogen 1987;29:9-21.
23. Berger R, Le CM, Derre J, Vecchione D, Pacot A, Chen SJ, Baranger L, Bernheim A. Cytogenetic studies on acute nonlymphocytic leukemia in relapse. Cancer Genet Cytogen 1988;34:11-8.
24. Abraham N, Jaramillo ML, Duncan PI, Methot N, Icely PL, Stojdl DF, Barber GN, Bell JC. The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia. Exp Cell Res 1998;244:394-404.
25. Li S, Koromilas AE. Dominant negative function by an alternatively spliced form of the interferon-inducible protein kinase PKR. J Biol Chem. 2001;epub before printing.
26. Beretta L, Gabbay M, Berger R, Hanash SM, Sonenberg N. Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q- associated leukemias. Oncogene 1996;12:1593-6.
27. Basu S, Panayiotidis P, Hart SM, He LZ, Man A, Hoffbrand AV, Ganeshaguru K. Role of double-stranded RNA-activated protein kinase in human hematological malignancies. Cancer Res 1997;57:943-7.
28. Hovanessian AG, Galabru J, Meurs E, Buffet JC, Svab J, Robert N. Rapid decrease in the levels of the double-stranded RNA-dependent protein kinase during virus infections. Virology 1987;159:126-36.
29. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
30. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
31. Patel CV, Handy I, Goldsmith T, Patel RC. PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR. J Biol Chem 2000;275:37993-8.
32. Polyak SJ, Tang N, Wambach M, Barber GN, Katze MG. The P58 cellular inhibitor complexes with the interferon-induced, double-stranded RNA-dependent protein kinase, PKR, to regulate its autophosphorylation and activity. J Biol Chem 1996;271:1702-07.
33. Donze O, Abbas-Terki T, Picard D. The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR. Embo J 2001;20:3771-80.
34. Tan SL, Tareen SU, Melville MW, Blakely CM, Katze MG. The Direct Binding of the Catalytic Subunit of Protein Phosphatase 1 to the PKR Protein Kinase Is Necessary but Not Sufficient for Inactivation and Disruption of Enzyme Dimer Formation. J Biol Chem 2002;277:36109-17.
35. Mathews MB. Control of translation in adenovirus-infected cells. [Review]. Enzyme 1990;44:250-64.
36. Manche L, Green SR, Schmedt C, Mathews MB. Interactions between double-stranded RNA regulators and the protein kinase DAI. Molec Cell Biol 1992;12:5238-48.
37. Corcoran MM, Rasool O, Liu Y, Iyengar A, Grander D, Ibbotson RE, et al. Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood 1998;91:1382-90.
38. Panayiotidis P, Ganeshaguru K, Hoffbrand AV, Rowntree C, Jabbar SA, Foroni L. Deletion of 13q14.3 and not 13q12 is the most common genetic abnormality detected in chronic lymphocytic leukemia cells. Blood 1997;89:734-5.
39. Stilgenbauer S, Nickolenko J, Wilhelm J, Wolf S, Weitz S, Dohner K, Boehm T, Dohner H, Lichter P. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocyfic leukemia and mantle cell lymphoma. Oncogene 1998;16:1891-7.
40. Liu Y, Corcoran M, Rasool O, Ivanova G, Ibbotson R, Grander D, Iyengar A, Baranova A, Kashuba V, Merup M, Wu X, Gardiner A, et al. Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 1997;15:2463-73.
41. Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, Guccione E, Qu X, Chien M, Murty VV, Gaidano G, Inghirami G, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001;97:2098-104.
42. Rowntree C, Duke V, Panayiotidis P, Kotsi P, Palmisano GL, Hoffbrand AV, Foroni L. Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEUI in B cell chronic lymphocytic leukemia. Leukemia 2002;16:1267-75.
43. Barber GN, Edelhoff S, Katze MG, Disteche CM. Chromosomal assignment of the interferon-inducible double-stranded RNA-dependent protein kinase (PRKR) to human chromosome 2p21-p22 and mouse chromosome 17 E2 1993;16:765-67.
44. Squire J, Meurs EF, Chong KC, McMillan NAJ, Hovanessian AG, Williams BRG. Localization of the human interferon-induced, dsRNA activated p68 kinase gene (PRKR) to chromosome 2p21-p22 1993;16:768-70.
45. Korth MJ, Edelhoff S, Disteche CM, Katze MG. Chromosomal assignment of the gene encoding the human 58-kDa inhibitor (PRKRI) of the interferon-induced dsRNA-activated protein kinase to chromosome 13q32. Genomics 1996;31:238-9.
46. Jeffrey IW, Bushell M, Tilleray VJ, Morley S, Clemens MJ. Inhibition of protein synthesis in apoptosis: differential requirements by the tumor necrosis factor alpha family and a DNA-damaging agent for caspases and the double-stranded RNA-dependent protein kinase. Cancer Res 2002;62:2272-80.
47. Der SD, Yang YL, Weissmann C, Williams BR. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci USA 1997;94:3279-83.
48. Srivastava SP, Kumar KU, Kaufman RJ. Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase. J Biol Chem 1998;273:2416-23.
49. Yeung MC, Liu J, Lau AS. An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. Proc Natl Acad Sci USA 1996;93:12451-5.